DAMORA THERAPEUTICS, INC. Debt Securities, Available-for-sale, Realized Gain (Loss)
DAMORA THERAPEUTICS, INC. (DMRA) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2026-03-19
- DAMORA THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-12-31 was $0.00.
- DAMORA THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-09-30 was $0.00.
- DAMORA THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2025 was $0.00.
- DAMORA THERAPEUTICS, INC. debt securities, available-for-sale, realized gain (loss) for fiscal 2024 was $0.00.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-19 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $0.00 10-K · filed 2026-03-19 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | $0.00 10-Q · filed 2024-11-01 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |